SGLT2 inhibitors use lowers cancer risk in patients with diabetes
Taiwan: Patients with diabetes who receive sodium-glucose cotransporter-2 (SGLT2) inhibitors are at a significantly lower risk of cancer, a new study published in the Journal of Diabetes and its Complications has shown.
There has been a substantial rise in the burden of diabetes mellitus, primarily through its atherosclerotic cardiovascular impact. Diabetes is also linked with cancer development, and this phenomenon's mechanism is complicated. With the proposal of novel antidiabetic agent SGLT2 inhibitors and its several pluripotent effects, identifying pharmacologic intervention's role in incident cancer among diabetes patients is genuinely novel and exciting. It holds importance for quality control efforts and health care delivery.
Against the above background, Wei-Syun Hu and Cheng-Li Lin from China Medical University, Taichung, Taiwan, aimed to evaluate the relationship between SGLT2 Inhibitors and incident cancer risk among diabetes patients with the examination of the large size of the database and the clinical importance of the question concerned.
The researchers identified a non-SGLT2 inhibitor cohort of 325,989 patients and an SGLT2 inhibitor cohort of 325,990 patients between 2016 and 2019. The study's primary interest was cancer occurrence. Hazard ratios (HRs) were estimated using univariate Cox proportional hazard models.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.